89bio (Nasdaq:ETNB) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ETNB Aperçu des actions

ETNB analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	2/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 79.19% par an

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Les actionnaires ont été dilués au cours de l'année écoulée

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

89bio, Inc. Concurrents

Viridian Therapeutics

NasdaqCM:VRDN

US$906.6m

MiMedx Group

NasdaqCM:MDXG

US$902.9m

Silence Therapeutics

NasdaqGM:SLN

US$886.4m

CARGO Therapeutics

NasdaqGS:CRGX

US$979.6m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour 89bio
Historique des cours de bourse
Prix actuel de l'action	US$8.33
Plus haut sur 52 semaines	US$18.06
Plus bas sur 52 semaines	US$6.58
Bêta	1.0
1Variation sur 1 mois	6.79%
Variation sur 3 mois	-11.95%
Variation sur 1 an	-51.37%
3Variation sur 3 ans	-58.47%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-59.95%

Nouvelles et mises à jour récentes

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

Recent updates

Rendement pour les actionnaires

	ETNB	US Biotechs	US Marché
7D	-5.1%	0.7%	-0.8%
1Y	-51.4%	15.1%	20.5%

Rendement vs Industrie: ETNB a sous-performé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: ETNB a sous-performé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is ETNB's price volatile compared to industry and market?
ETNB volatility
ETNB Average Weekly Movement	9.3%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: ETNB n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ETNB ( 9% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2018	70	Rohan Palekar	www.89bio.com

89bio, Inc. est une société biopharmaceutique en phase clinique qui se concentre sur le développement et la commercialisation de thérapies pour le traitement des maladies hépatiques et cardio-métaboliques. Son principal produit candidat est la pegozafermine, un analogue glycoPEGylé du facteur de croissance des fibroblastes 21 pour le traitement de la stéatohépatite non alcoolique ; et pour le traitement de l'hypertriglycéridémie sévère. La société a été constituée en 2018 et son siège social se trouve à San Francisco, en Californie.

89bio, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de 89bio se comparent-ils à sa capitalisation boursière ?
ETNB statistiques fondamentales
Capitalisation boursière	US$896.00m
Bénéfices(TTM)	-US$174.61m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-5.1x

Ratio P/E

Le site ETNB est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ETNB compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$174.61m
Les revenus	-US$174.61m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.65
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	4.9%

Quelles ont été les performances à long terme de ETNB?

Voir les performances historiques et les comparaisons

ETNB Aperçu des actions

Récompenses

Analyse des risques

89bio, Inc. Concurrents

NasdaqCM:VRDN

US$906.6m

NasdaqCM:MDXG

US$902.9m

NasdaqGM:SLN

US$886.4m

NasdaqGS:CRGX

US$979.6m

Historique des prix et performances

Nouvelles et mises à jour récentes

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

Recent updates

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company

89Bio Completes Target Enrollment in Histology Cohort to Evaluate Bio89-100 for the Treatment of Nash

Price target decreased to US$52.50

89bio: Undervalued Contender In Race For First NASH Drug Approval